WCLC 2025 - Posters & ePosters-P2.15 .05 A Shared Decision Aid for First-Line Treatments of ALK+ Advanced Non-Small Cell Lung Cancer: A Patient-Centered Approach

P2.15 .05 A Shared Decision Aid for First-Line Treatments of ALK+ Advanced Non-Small Cell Lung Cancer: A Patient-Centered Approach

Back to course

Pdf Summary

This study reports the development and testing of the first digital decision aid (DA) designed to support shared decision-making for first-line (1L) tyrosine kinase inhibitor (TKI) treatments in patients newly diagnosed with ALK-positive advanced non–small cell lung cancer (aNSCLC). Given multiple TKI options with varying risk-benefit profiles and limited direct comparative data, patients face challenging treatment decisions. Prior preference research showed patients value efficacy and are willing to make trade-offs but preferences vary widely, underscoring the need for tools that support individualized decisions.<br /><br />Researchers conducted formative qualitative interviews with 11 patients and 3 oncologists to inform the DA’s content and design, supplemented by feedback from patient advisors and clinical experts. The DA includes education on TKIs, key differences between available options, links to resources, and a quantitative values clarification activity (VCA) using best-worst scaling where users identify the most and least important treatment features. This generates an individualized report listing prioritized attributes, plus question prompts to guide patient-provider discussions.<br /><br />User testing with 7 patients showed the DA was well received, perceived as balanced and informative, and helped users deliberate thoughtfully about treatment priorities such as cancer control duration and side effect profiles. Patients reported the VCA was challenging but meaningful, and the individualized report helpful for shared decision-making. Oncologists also supported the DA’s value in patient education and preference elicitation, suggesting minor content refinements.<br /><br />Overall, the DA promises to empower newly diagnosed patients by improving knowledge, reducing decisional conflict, and aligning treatment choice with personal values. It has been added to the ALK Positive patient advocacy website and will be disseminated further via Go2Lung in 2025. The study highlights the importance of providing accessible, patient-centered decision support tools at diagnosis to aid complex ALK aNSCLC treatment decisions.

Asset Subtitle

Thomas Stinchcombe

Meta Tag

Speaker Thomas Stinchcombe

Topic Multidisciplinary Care: Nursing, Allied Health and Palliative Care

Keywords

digital decision aid

shared decision-making

tyrosine kinase inhibitor

ALK-positive

advanced non-small cell lung cancer

patient preferences

values clarification activity

treatment decision support

patient education

individualized treatment report